Drugs / EXO-CD24
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04747574 | Sep 2020 → Feb 2021 | COVID-19 | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05947747 | Jul 2023 → Dec 2025 | acute respiratory distress syndrome | Nano24med | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXO-CD24 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05947747 ↗ |
| Known as | EXO-CD24 -exosomes | “The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline...” NCT04747574 ↗ |
| Modality | Other / unclassified | “The treatment is a biologic therapeutic agent based on exosomes carrying CD24.” NCT04747574 ↗ |
| Route | Inhaled | “aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device” NCT04747574 ↗ |
| Target | CD24 | “The treatment is a biologic therapeutic agent based on exosomes carrying CD24.” NCT04747574 ↗ |